Latest News and Press Releases

MAPS names Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors, bringing decades of drug policy expertise.

SAN JOSE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve...

MAPS selects Changemark as CRO for $12.9M Phase 2 cannabis PTSD study in Veterans, advancing toward Q1 2026 treatment start.

Enhanced Virtual Trip platform goes live with improved user experience and first selection of PS2025 session videosConference drew 8,000+ attendees, more than $1 million donated, and 1,100+ recurring...

Nearly 60 Ukrainian therapists will attend the event at no cost, learning fundamentals and best practices for psychedelic-assisted therapieAlpha XR than 300 practitioners from more than 30 countries have...

In January, the U.S. Sentencing Commission announced proposed amendments to federal drug sentencing guidelines, including lowering the highest base offense level for drug sentences.The proposal also...

MAPS’ next Executive Director will be a bold movement leader and visionary responsible for implementing MAPS' new strategic impact plan, ensuring programmatic excellence, advancing global expansion,...

MAPS’ “Music is the Bridge” blends artist playlists & free psychedelic education, inspiring exploration and connection. Visit MAPS.org/music-is-the-bridge

World’s leading psychedelic conference kicks off with workshops from leaders in science, medicine, therapy, policy, Indigenous medicine, and societyUpcoming deadline: speaker submissions, initial...

After three years of negotiation with the FDA, MAPS has successfully secured FDA clearance to conduct a clinical trial, MJP2, to examine the use of smoked cannabis for the treatment of PTSD symptoms...